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ABSTRACT 
 
Antidiabetic drugs are widely available in the market, but most medications have strong side 
effects that may cause toxicity. Therefore, a search for new drug compounds that are more potent 
but with lower side effects is necessary. Various research has shown that bitter melon (Momordica 
charantia L) exhibits antidiabetic activities. However, the compounds in this plant that actively acts 
as potent antidiabetic are not specifically known yet. This study aimed to identify these active 
compounds in silico through molecular docking, drug scan, PreADMET, and molecular dynamics 
simulation. The test results of the 26 active compounds in bitter melon showed one potential 
compound that was actively against the nuclear receptor RORα, i.e., Goyaglicoside-h, and more 
potent than Rosiglitazone. 
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INTRODUCTION 
Diabetes Mellitus (DM) remains a very troubling health problem worldwide. The 
International Diabetes Federation (IDF) states that the prevalence of DM is 1.9%, which makes 
DM the seventh major cause of death in the world. In 2012, an estimated 371 people were living 
with DM. The global incidence of type 2 DM is 95%, whereas the remaining 5% of the world’s 
population has type 1 DM (Fatimah, 2015). 
Drug research and development have been vastly conducted, including the search for 
medicinal compounds from natural ingredients. One of them is a bitter melon, which is listed in the 
Materia Medika Indonesia Vol. VI/1995 as a medicinal plant whose fruit is efficacious as an 
antidiabetic medication (Indonesian Ministry of Health, 1995). Yuda et al. (2013) reveal that the 
administration of the ethanolic extract of bitter melon (Momordica charantia) can reduce blood 
glucose levels in white rats (Rattus norvegicus) subjected to alloxan-induced diabetes. 
Furthermore, Mulyanti et al. (2010) have successfully isolated two compounds of the triterpenoid 
group from the active fraction (n-hexane) of bitter melon as an antihyperglycemic agent. 
Previous studies have identified several active compounds in bitter melon, namely the 
derivatives of cucurbitane triterpenoids (Murakani et al., 2001; Yoshikawa et al., 2007; Nakamura 
et al., 2006). Several in vitro studies also confirm the antidiabetic activity of cucurbitane 
triterpenoid through different types of screening and testing (Harinantenaina et al., 2006; Jiang et 
al., 2016; Chawech et al., 2015). Aside from in vitro, in silico research can be used to study the 
interactions between compounds and enzymes, receptors, or pharmacokinetic properties to predict 
the drug candidates for certain diseases (Ruswanto et al., 2018). Therefore, to predict and test the 
antidiabetic potential of the previously identified active compounds, this research employed in 
silico design through the identification of receptor target and other in silico tests.  
  
RESEARCH METHOD 
Tools 
This research used computer hardware and software. The device was a personal computer 
with Intel (R) Core (TM) i3 and the following specifications: CPU M 380 @ 2.53GHz (4 CPUs), 
2.5GHz 2048MB RAM, and software, such as Pendrivelinux, MarvinSketch v.5.2, YASARA 
v.9.10, PLANTS, and LigPlot (Ruswanto et al., 2015). 
Materials 
This research processed the PDB (Protein Data Bank) files of the identified receptor, which 
were downloaded from http://www.rscb.org. and 26 active cucurbitane-type triterpene glycosides 
contained in bitter melon (see Table II).  
Research Procedure 
Ligand preparation  
 The ligands were prepared by drawing the chemical structures on Marvin sketch, 
protonated until pH 7.4 was achieved, and saved as .mrv  files. The conformations were saved as 
.mol2 files. This procedure was performed on all ligands (Ruswanto et al., 2015; Ruswanto et al., 
2017) 
Receptor identification 
 The structures of the compounds (.mol2 files) were uploaded to PharmMapper web server. 
This web server assigns a JOB ID to every modeling with which users can check the mapping 
results. The output was the list of the top 300 targets that were subjected to further evaluation to 
select the candidates for antidiabetics. Receptors with PDB codes were downloaded from 
http://www.rscb.org (Liu et al., 2010). 
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Protein analysis 
The protein resulted from the identification of the receptor target was analyzed with the 
Ramachandran plots of PDB protein at http://www.ebi.ac.uk/pdbsum/. For protein target search, 
users can access the profiles using the four characters in PDB codes (Gunasekaran et al., 1996; 
Ruswanto et al., 2018). 
 
Table I.  The active compounds of bitter melon plants (Murakani et al., 2001; Yoshikawa et al., 2007; 
Nakamura et al., 2006) 
No Senyawa No Senyawa 
1 Momordicin I 
OHC
HO
H3C CH3
OH
CH3
H
CH3
CH3
H3C
HO
H3C
 
7 (23E)-3ß-Hidroksi-7ß-metoksi-kukurbita-5,23,25-
trien-19-al  
OHC
OCH3
HO
H3C CH3
CH3
H
CH3
CH2
H3C
H3C
 
2 Momordicin II 
OHC
HO
H3C CH3
OH
CH3
H
CH3
CH3
H3C
O
H3C
O
OH
OH
HO
CH2OH
 
8 (23E)-3ß-Hidroksi-7ß,25-dimetoksi-kukurbita-5,23-
dien-19-al 
OCH3
OHC
OCH3
HO
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
 
3 25-Hidroksi-23-dehidroksi-
momordicin I 
OHC
HO
H3C CH3
OH
CH3
H
CH3
CH3
H3C
H3C
OH
 
9 (19R,28E)-5ß,19-Epoksi-19-metoksikukurbita-
6,23,25-trien-3ß-ol 
H3CO
HO
H3C CH3
CH3
H
CH3
CH2
H3C
H3C
O
H
 
4 25-metoksi-23-dehidroksi-momordicin 
I 
OHC
HO
H3C CH3
OH
CH3
H
CH3
CH3
H3C
H3C
OCH3
 
10 (19R,23E)-5ß,19-Epoksi-19-metoksikukurbita-
6,23,dien-3ß,25-diol 
OCH3
HO
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
OH
 
5 3ß,7ß,23-Trihidroksikukurbita-5,24-
dien-7-O_ß-D-glukosida 
11 (19R,23E)-5ß,19-Epoksi-19,25-
dimetoksikukurbita-6,23-dien-3ß-ol 
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CH3
HO
H3C
O
CH3
H3C
H3C
CH3
CH3
CH3
O
OH
OH
HO
CH2OH
HO
 
OCH3
OCH3
HO
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
 
6 Momordicin 
III
OHC
HO
H3C CH3
OH
CH3
H
CH3
CH2
H3C
H3C
O
O
OH
OH
HO
OH
 
12 Momordikosida A 
CH2OH
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OH
OH
HO
OH
OH
OH
HO
CH3
O
O
OH
OH
HO
 
13 Momordikosida C 
CH2OH
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OH
OH
HO
OH
OH
HO
CH3
O
O
OH
OH
HO
 
19 Goyaglikosida-a 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
OH
O
OH
OH
HO
OCH3
CH2OH
 
14 Momordikosida F1 
OCH3
CH2OH
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OH
OH
HO
O
 
20 Goyaglikosida-b 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
OH
O
OHOH
HO
OH
OCH3
 
15 Momordikosida F2 
CH2OH
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OHOH
HO
OH
O
 
 
 
 
 
 
 
21 Goyaglikosida-c 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
O
OH
OH
HO
H3CO
OCH3
HOH2C
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25 Goyalikosida-g 26 Goyalikosida-h 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OH
OH
HO
OH
O
OH
HO
CH3
O
O
OH
OH
HO
CH2OH
 
 
16 Momordikosida G 
CH2OH
OCH3
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OHOH
HO
O
 
22 Goyaglikosida-d 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
O
OHOH
HO
OCH3
CH2OH
OCH3
 
17 Momordikosida I 
CH2OH
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
H
O
OH
OH
HO
OH
O
 
23 Goyalikosida-e 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
O
O
OHOH
HO
OH
OH
HO
OH
CH2OH
 
18 Momordikosida K 
OHC
HO
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
O
OH
OH
HO
CH2OH
OCH3
 
24 Goyalikosida-f 
O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
O
OH
OH
HO
O
O
OHOH
HO
CH2OH
H3CO
CH2OH
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O
H3C CH3
CH3
H
CH3
CH3
H3C
H3C
O
H
O
OHOH
HO
O
O
OH
OH
HO
CH2OH
CH2OH
OH
 
 
 
Molecular Docking 
Receptor preparation 
 The protein (PDB) was downloaded from http/www./rscb.org/ and re-prepared in 
YASARA software. The results were saved in two files, namely protein.mol2 for the target 
receptor and ref_ligand.mol2 for the ligand comparator during the receptor validation process 
(Purnomo, 2013). 
Receptor docking validation 
 The two files resulted from the preparation process, namely protein.mol2 and 
ref_ligand.mol2, were docked using PLANTS program that had been linked to Co-pendrivelinux. 
The complex of ref_ligand-protein with the lowest ‘best score’ was calculated with Root Mean 
Square Deviation (RMSD) value. A receptor was declared as valid and applicable as a test ligand if 
its RMSD was < 2 (Purnomo, 2013). 
 
Test ligand docking 
 The ligand docking of the active compounds of bitter melon was performed in PLANTS 
software that had been linked to Co-pendrivelinux. The results of the docking were the best scores 
of the test ligands that were compared with the best score of the ligand comparator obtained from 
the docking simulation. Furthermore, the protein-test ligand complex with a lower best score than 
the ligand comparator was visualized and interpreted to identify any molecular interactions 
(Purnomo, 2013). The position of each amino acid residue bound to the ligand was visualized in 
two dimensions (2D) in Ligplot (Wallace et al., 1996). 
 
Molecular Dynamics (MD) simulation 
The molecular dynamics simulations of the protein-test ligand complexes, obtained from the 
docking, used MOE software v.2009. The simulation system involved the influence of temperature 
and solvent and used the Born solvation. The temperature of the simulation was 310 K (the normal 
temperature of a human body) (Kurniawan et al., 2018). 
 
Drug scanning  
The drug scan analysis was performed on ligands that had lower binding energy than the 
compound comparator. It also applied the Lipinski’s parameter in MarvinSketch software 
(Tambunan et al., 2012; Athar et al., 2017; Choy and Prausnitz, 2011). 
 
ADMET Study 
 The ADME (Absorption, Distribution, Metabolism, and Excretion) study was conducted in 
the PreADMET web-based program—accessible at http://preadmet.bmdrc.org/, using the Caco-2 
cell (Carcinoma colon bilayer) permeability parameters,  HIA (Human Intestinal Absorption), and 
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plasma protein binding (PPB). The toxicity parameters were observed from the carcinogenic and 
mutagenic properties of the compounds (Ruswanto et al., 2017).  
 
RESULTS AND DISCUSSION 
This study began with the stage of ligand preparation, which aimed to optimize the geometry 
of the test compounds contained in bitter melon plants using protonation until these compounds had 
the same pH as human blood, i.e., 7.4. Afterward, the protonated test compounds were subjected to 
further search for other conformations that were expected to be more stable when docked to the 
receptor. This conformation is very important in determining the drug-receptor interactions as it 
displays the spatial position of the atoms or groups relative to the receptor in the compound 
structures. It has a high affinity for forming stable bonds.  
 
Receptor identification 
The pharmacophore mapping approach on the PharmMapper web server resulted in the list 
of the top 300 targets of PDB (Protein Bank Data) IDs. The data were then evaluated to identify the 
suitable diabetes mellitus receptors. The evaluation results showed that there were two targets at 
the top 10 rankings, namely Nuclear receptor ROR alpha (PDB Code 1S0X) and Retinol-binding 
protein 4 (PDB Code 1RBP). Both targets are described in Table II. 
 
Table II. Receptor targets 
 
Ranks 
PDB 
IDs 
Receptor Targets 
Fit 
Scores 
1 1S0X Nuclear receptor ROR alpha 6.013 
7 1RBP Retinol-binding protein 4 4.906 
 
However, only one of the receptors with the highest fit score was selected, i.e., 1S0X. The 
higher the fit score, the higher the affinity of the pharmacophore group in the ligand and the more 
suitable the receptor. This research identified ten (10) pharmacophore groups that were suitable to 
the ligand and 1S0X receptor. They consisted of seven (7) hydrophobic groups, one (1) negative, 
and two (2) acceptors, as shown in Figure 1. 
 
 
 
 
 
 
 
 
 
Figure 1.  The pharmacophore of cucurbitacin compounds  
 
ROR (Related Orphan Receptor) is one type of PPAR (Peroxisome Proliferator-Activated 
Receptors) receptor in humans which belongs to the nuclear receptor group. It is found in liver, 
muscle, and adipose tissue. It plays a role in several biological processes in the body, including 
glucose metabolism. Furthermore, it is indicated to have the potential as the therapeutic target in 
diabetes mellitus treatment (Kojetin and Burris, 2014). 
Kojetin and Burris (2014) explain that one of the ligands bound to the receptor RORα is a 
diabetes mellitus drug from the thiazolidinedione group, namely Rosiglitazone. Therefore, this 
study used Rosiglitazone as a comparator in determining the effectivity of the test ligands.  
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Protein Analysis 
1S0X was analyzed on the pdbSUM web server using the Ramachandran plot to identify the 
stability of the protein. Ramachandran plot is used to visualize the three-dimensional coordinates of 
proteins obtained from experiments in protein structure (using the internal coordinates). Every 
amino acid residue can be depicted as a region in the Ramachandran plot because it has one 
dihedral angle Φ (phi) and one dihedral angle ψ (psi), which constitute the internal coordinates in 
the three-dimensional coordinates of a protein (Torshin et al., 2016). The results of the receptor 
analysis can be seen in Figure 2 and Table III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  The Ramachandran plot of the receptor (1SOX) before molecular dynamics 
(MD) simulation  
 
 
Table III. The ramachandran plot statistics 
 
Categories 
No. of 
Residues 
Percentage 
Most favored regions [A,B,L] 659 89.3% 
Additional allowed regions [a,b,l,p] 76 10.3% 
Generously allowed regions [~a,~b,~l,~p] 1 0.1% 
Disallowed regions [XX] 2 0.3% 
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Based on the analysis results presented in Figure 2 and Table III, the disallowed region on 
the Ramachandran plot for non-glycine residues is smaller than 15%, indicating that the protein in 
1S0X is stable and can be used for the next step in this study.  
Non-glycine residues are unfavorable because the presence of residues other than glycine in 
this region can cause a steric obstruction, which potentially interferes with the conformation of 
protein to create a stable bond with the ligand (Gunasekaran et al., 1996). 
 
Receptor validation 
This step involved the redocking of the natif_ligand C3S (cholesterol sulfate) to the receptor 
1S0X using the same procedure as the docking in this study, which was performed in PLANTS. 
Afterward, the comparison between the C3S obtained from the redocking and the C3S on the PDB 
file resulted in Root Mean Square Deviation (RMSD), and the results of the crystallography were 
downloaded from the Protein Data Bank.  
 
 
Figure 3. The comparison between the conformation of the crystal structure of C3S (red) and 
the docking results in the PLANTS program (blue) 
 
The analysis in the YASARA program showed that the RMSD was 1.22 Å, indicating that 
the conformation of the redocking results is similar to the results of the x-ray crystallography. This 
RMSD also proves that the PLANTS method is valid for the docking of the test compound to the 
receptor 1S0X. 
 
Test ligand docking 
The free-energy of binding of the test compound-1S0X docking was compared with 
Rosiglitazone, which is an antidiabetic drug from the thiazolidinedione group. ∆G represents the 
strength of the affinity of the ligand-receptor binding. The smaller the value of ∆G, the higher the 
affinity. In other words, the ligand-receptor bond becomes more stable because the reaction occurs 
spontaneously (Levita and Mustarichie, 2012). The results of the docking between the test ligand 
and 1S0X are summarized in Table IV.  
The affinity (∆G) of the ligand comparator (i.e., Rosiglitazone) was -47.24 kcal/mol. Among 
the 26 test compounds in bitter melon plants, 14 of them had higher free-energy of binding than 
Rosiglitazone, namely Goyaglycoside-h, Goyaglycoside-g, Momordicoside F1, Momordicoside G, 
Goyaglycoside-d, Goyaglycoside-c, Momordicosida I, Momordicoside F2, Goyaglycoside-b, 
Goyaglycoside-a, Goyaglycoside-f, Goyaglycoside-e, Momordicoside K, and Momordicin II. 
Goyaglycoside-h had the least free energy (-90.4438 kcal/mol), meaning that the interaction 
between Goyaglycoside-h and 1S0X is the most stable among the other test ligands.  
 
Visualization 
To analyze the interactions occurring in the protein ligands, the docking results were 
visualized in two dimensions in the LigPlot program. Figures 4 and 5 are the visualizations of the 
binding of native ligand and Rosiglitazone to the receptor RORα (Laskowski and Swindells, 2011; 
Ruswanto et al., 2015). 
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Figure 4. The visualization of the native ligand 
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Table IV. The bonding  energy of  the docking  result 
 
Ligands 
∆G 
(kcal/mol) 
Rosiglitazone* -47.24 
Momordicin I -42.65 
Momordicin II -49.00 
Momordicin III -44.96 
25-Hydroxy-23-dihydroxy-momordicin I -44.73 
25-Methoxy-23- dihydroxy-momordicin I -43.44 
3B,7B,23-Trihydroxycucurbita-5,24-dien-7-O_B-D-glucoside -46.21 
(23E)-3B-Hydroxy-7B,25-dimethoxy-cucurbita-5,23-dien-19-al -43.51 
(23E)-3ß- Hydroxy-7ß-methoxy-cucurbita-5,23,25-trien-19-al -41.12 
(19R,23E)-5ß,19-Epoxy-19,25-dimethoxycucurbita-6,23-dien-3ß-ol -41.77 
(19R,23E)-5ß,19- Epoxy-19-methoxycucurbita-6,23,dien-3ß,25-diol -44.89 
(19R,28E)-5ß,19- Epoxy-19- methoxycucurbita -6,23,25-trien-3ß-ol -40.85 
Goyaglicoside-a -59.59 
Goyaglicoside-b -59.80 
Goyaglicoside-c -60.31 
Goyaglicoside-d -60.49 
Goyaglicoside-e -49.34 
Goyaglicoside-f -58.48 
Goyaglicoside-g -63.93 
Goyaglicoside-h -90.44 
Momordicoside A -46.62 
Momordicoside C -46.60 
Momordicoside F1 -60.59 
Momordicoside F2 -59.97 
Momordicoside G -60.51 
Momordicoside I -60.11 
Momordicoside K -50.44 
 
*Rosiglitazon= comparator 
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 Figure 5. The visualization of Rosiglitazone 
 
 
Notes: C= black, O= red, N= blue 
Hydrogen bond = green dashed lines 
Hydrophobic bod = eyebrow-shaped red lines 
 
 
Figure 4 shows that the binding sites of the native ligand consist of hydrogen bonds with the 
amino acid residues Tyr290, Cys288, and Arg370 and hydrophobic bonds with Arg367, Gln289, 
Tyr380, Met368, Ala371, Ile327, His484, Cys323, Trp320, Lys326, and Ala330 (with hydrophobic 
bonds). Meanwhile, in Figure 5, hydrophobic interactions are found in the binding sites of 
Rosiglitazone near the amino acid residues Arg370, Leu410, Val427, Ser424, Leu428, Glu362, and 
Val334.  
Some test ligands have similarities with the native ligand, i.e., bound to the residue Arg370 
hydrophobically (such as Momordicoside K, Goyaglicoside-b, Goyaglicoside-c, Goyaglicoside-d 
and hydrophobically) and with hydrogen bonds (Momordicin II). Momordicin II and 
Goyaglicoside-g are also bound to Ala371 and Ile327 hydrophobically. Meanwhile, 
Momordicoside K is also bound to Met368 with hydrogen bonds. The binding of Goyaglycoside-h 
to Lys326 and Ile327, as well as Goyaglycoside-e to Lys326, also involve hydrogen bonds. 
Furthermore, all test ligands occupy the same binding sites as Rosiglitazone, which is around 
Arg370, Leu410, Val427, Ser424, Leu428, Glu362, and Val334 either with hydrophobic or 
hydrogen bond. Such a similarity is very important for the generated pharmacological effects. The 
ligands are, thereby, predicted to exhibit activities on the receptor because they occupy the same 
binding sites as the native ligand and drug comparator.  
 
Drug scan 
The drug scan analysis aimed to examine the similarity of the properties of the test ligand 
and the existing drugs (drug-likeliness) and refer it to the similarity of a certain compound to oral 
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drugs. The Lipinski’s rule can help to distinguish between drug-like and non-drug-like molecules 
by considering their level of absorption and permeability through the lipid bilayers in the human’s 
body (Harganingtyas, 2011). This rule stipulates that molecules must have a molecular mass <500 
g/mol, a partition coefficient (log P) <5, less than 5 hydrogen bond donors, less than 10 hydrogen 
donor acceptors, and molar refractivity between 40-130 (Wulandari, 2010). 
Molecular mass and log P determine the ability of a compound to permeate the lipid bilayer 
of the epithelial tissue that lines the intestinal surface, which is penetrable only by small and 
sufficiently hydrophobic molecules. A greater log P indicates a more hydrophobic and fat-soluble 
molecule. In other words, the molecule can easily penetrate the membrane barrier. However, 
compounds that are too hydrophobic tend to have greater toxicity because the drug molecules are 
held within the lipid bilayers in a long time and cannot be excreted from the body (Wulandari, 
2010).  
The hydrogen bond donors and acceptors are the major contributors to the polar surface area 
of a molecule. The wider the area, the lower the permeability. Therefore, molecules with many H-
donors and H-acceptors hardly infiltrate the membrane barrier (Wulandari, 2010). 
 
Table V. The results of the Lipinski’s rule application 
 
Ligands 
The Lipinski’s Rule of Five 
Molecular 
Mass 
Log P 
H-
Donors 
H-
Acceptors 
Molar 
Refractivity 
Goyaglicoside-h 814.99 0.81 10 15 204.21 
Goyaglicoside-g 811.00 2.22 8 14 207.20 
Momordicoside F1 632.86 4.35 4 8 173.75 
Momordicoside G 632.86 4.35 4 8 173.75 
Goyaglicoside D 662.89 4.63 4 9 179.53 
Goyaglicoside C 662.89 4.63 4 9 179.53 
Momordicoside I 618.84 3.71 5 8 169.00 
Momordicoside F2 618.84 3.71 5 8 169.00 
Goyaglicoside-b 648.86 3.99 5 9 174.78 
Goyaglicoside-a 648.86 3.99 5 9 174.78 
Goyaglicoside-f 811.00 2.26 8 14 206.76 
Momordicoside K 648.86 3.23 5 10 176.15 
Goyaglicoside-e 779.00 1.89 8 12 205.15 
Momordicin II 664.90 2.63 6 10 170.97 
Rosiglitazon* 357.42 3.08 1 7 97.79 
*Rosiglitazon= comparator 
 
Based on the analysis results presented in Table V, all test compounds do not meet with the 
Lipinski’s rule because the molecular mass is greater than 500 g/mol and the molar refractivity is 
not within the range of 40-130.  
 
ADMET STUDY 
The compounds resulted from the docking process were analyzed pharmacokinetically to 
assess their absorption, distribution, metabolism, and excretion abilities in the body. Absorption is 
the process of transferring the drug from its site of application to the systemic circulation and 
leaving a sufficient concentration to produce the desired drug effect. Because the drug is 
administered orally, it can experience a first pass effect, i.e., metabolism in several organs like the 
small intestines, blood, and liver, even before reaching the systemic circulation (Nugroho, 2012). 
Distribution is the transfer of drugs from the systemic circulation to an area (fluid and 
tissues) in the body with the help of blood plasma proteins. However, in this case, only the free 
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compounds (not protein-bound) in the drugs can penetrate the body’s tissues. Drugs that are 
strongly bound to proteins have a larger molecular size that prevents them from infiltrating the 
membrane pores to reach the body tissues (Nugroho, 2012). 
Table VI lists the data of permeability, HIA absorption, and the percentage of plasma protein 
binding for each test ligand. Drug compounds must have good permeability and absorption ability 
in the intestines and not be bound strongly to plasma proteins to reach the target receptors and 
produce the desired biological activity. Based on the evaluation results, five test ligands met the 
criteria, namely Goyaglicoside-a, Goyaglicoside-b, Goyaglicoside-c, Goyaglicoside-d, and 
Momordicoside K. 
In addition to ADME study, the pharmaceutical candidate compounds were subjected to 
toxicity test. This test can ensure that these compounds are safe for use. The drug toxicity can be 
acute (related to the administration of toxic substance) or chronic because the human’s body is 
exposed to a small amount of substance over a long period―where this substance accumulates and 
reaches a toxic concentration that leads to the symptoms of poisoning (Mutschler, 1999). 
 
Table VI. The ADME analysis results 
 
Ligands 
Caco-2 Cells 
Permeability 
HIA 
Absorption 
Plasma Protein 
Binding 
(%PPB) 
Rosiglitazone 28.61 S 97.45 B 91.09 K 
Goyaglicoside-h 18.55 S 7.19 k 59.32 L 
Goyaglicoside-g 18.07 S 43.15 S 68.36 L 
Momordicoside F1 28.80 S 90.25 B 91.36 K 
Momordicoside G 28.80 S 90.25 B 91.36 K 
Goyaglicoside-d 28.80 S 90.11 B 89.08 L 
Goyaglicoside-c 28.80 S 90.11 B 89.08 L 
Momordicoside I 20.50 S 85.12 B 93.13 K 
Momordicoside F2 20.50 S 85.12 B 93.13 K 
Goyaglicoside-b 21.81 S 84.75 B 89.54 L 
Goyaglicoside-a 21.81 S 84.75 B 89.54 L 
Goyaglicoside-f 18.48 S 43.19 S 76.93 L 
Momordicoside K 20.83 S 84.03 B 87.59 L 
Goyaglicoside-e 17.51 S 53.89 S 75.85 L 
Momordicin II 20.16 S 74.14 B 91.12 K 
Notes: B (Good), S (Fair), k (Poor); K (Strong), L (Weak), *(Comparator) 
 
In this study, the toxic effects could only be ascertained after a fairly long (chronic) latent 
period through mutagenic and carcinogenic properties. Mutagens are compounds that cause 
changes in basic DNA sequences and, subsequently, in proteins encoded by genes (Mutschler, 
1999), while carcinogens are the ones that transform DNA and change normal cells to tumor cells, 
initiating tumor growth. Therefore, the effects of carcinogens are closely related to mutagenic 
properties, interpreted as mutagenic effects (Mutschler, 1999). 
The mutagenicity of the compounds was predicted using the preADMET program based on 
the presence of structure alerts—which, according to Pratiwi et al. (2014), shows that the 
compounds have functional groups that can cause mutations in S. typhimurium in the Ames Test. 
Based on the results summarized in Table VII, the 14 test compounds are non-mutagenic but 
positive for carcinogens when administered to mice, except for Goyaglycoside-h, Goyaglycoside-f, 
and Momordicoside K. 
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Table VII. The toxicity test results 
 
 
Ligands 
Toxicity 
Mutagenic Carcinogenic 
Ames_test Carcino_ Mouse Carcino_Rat 
Rosiglitazone* Mutagenic - - 
Goyaglycoside-h Non-mutagenic + - 
Goyaglycoside-g Non-mutagenic + + 
Momordicoside F1 Non-mutagenic + + 
Momordicoside G Non-mutagenic + + 
Goyaglycoside-d Non-mutagenic + + 
Goyaglycoside-c Non-mutagenic + + 
Momordicoside I Non-mutagenic + + 
Momordicoside F2 Non-mutagenic + + 
Goyaglycoside-b Non-mutagenic + + 
Goyaglycoside-a Non-mutagenic + + 
Goyaglycoside-f Non-mutagenic + - 
Momordicoside K Non-mutagenic + - 
Goyaglycoside-e Non-mutagenic + + 
Momordicin II Non-mutagenic + + 
*Rosiglitazone= comparator 
 
Molecular Dynamics (MD) 
The molecular dynamics simulation was performed on one of the best candidate test 
compounds based on the previous analysis results, namely Goyaglycoside-h ligand that forms a 
complex with the receptor RORα, the output of the docking process. This simulation was carried 
out using the dynamic MOE (Molecular Operating Environment) program v.2009. The protein was 
positioned in a flexible state and influenced by solvents. The simulation used Born solvation, which 
is an explicit system. Proteins are naturally surrounded by solvents; therefore, the generated energy 
is influenced by their interaction with the solvation system. 
 
 
Figure 6. The visualization of the Molecular Dynamics (MD) simulation results 
 
Before the simulation, the minimization stage was performed to relax the system by 
adjusting the geometric position of the atoms to obtain the lowest energy for the system (Nurbaiti, 
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2009). Furthermore, the simulation was run for 2,000 ps at 310 K. The addition of temperature as 
an influencing factor aimed to create a simulation system that resembled the normal condition of a 
human body. Temperature can affect the stability of the drug-receptor complex. 
Figure 6 shows that after the MD simulation, the glycoside-h is attached to the amino acid 
residues Gln289, Thr287, Ser283, Gly407, Phe404, Gln274, and Glu419 by forming hydrogen 
bonds and to the residues Glu286, Ser409, Leu276, Ser412, Leu273, Gln375, Phe402, Cys411, 
Val354, Phe406, and Tyr385 hydrophobically. 
Based on the changes in the type and amount of contact residues, the binding sites of 
Goyaglycoside-h has shifted due to the conformation of the protein. One residue remains 
interacting hydrophobically, namely Phe406. However, the ligand does not emerge from the 
protein, which shows that the complex formed between the ligand and the receptor is stable at 310 
K. 
The stability of the complex produced from the docking process is observable from the 
stability of the protein conformation by analyzing the generated Ramachandran Plot. The plot of 
the PDB files of the complex was analyzed on the Rampage web server. The stability of the protein 
was determined from the number of non-glycine residues in the disallowed region. The results are 
presented in Figure 7. 
 
 
Figure 7.  The Ramachandran Plot for 1S0X after MD Simulation 
 
The plot depicts the position of amino acid residues at the dihedral angle Φ (phi) and Ψ (psi) 
of the peptide bond. The total number of the residues in the entire area is shown in Table VIII. 
 
Table VIII. The ramachandran plot Statistics after MD simulation 
 
Categories 
No. of 
Residues 
Percentage 
Most favored regions [A,B,L] 222 89.2% 
Generously allowed regions [~a,~b,~l,~p] 27 10.8% 
Disallowed regions [XX] 0 0.0% 
 
Table VII shows that the number of non-glycine residues in the disallowed regions is 0.0%. 
Because it is not larger than 15%, the protein after being subjected to molecular dynamics 
simulation is considered stable. 
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CONCLUSION 
Based on the pharmacophoric properties, the cucurbitacin compounds are concluded as 
active against the receptor RORα (Related Orphan Receptor alpha). Furthermore, the free-energy 
of binding from the molecular docking of the 26 cucurbitacin compounds in bitter melon plants (M. 
charantia) shows that Goyaglycoside-h is the best ligand. The molecular dynamics simulation 
results at a temperature of 310 K for 2,000 ps confirmed the stable interaction of the complex of 
Goyaglycoside-h and nuclear receptor RORα. Based on the in silico study, the active compound in 
bitter melon plants (M. charantia) that is a potential candidate for antidiabetic medication is 
Goyaglycoside-h. 
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